Fluoxetine <i>v</i>. placebo in prevention of relapse in post-traumatic stress disorder

Martényi, Ferenc; Brown, Eileen; Zhang, Harry; Koke, Stephanie C.; Prakash, Apurva

doi:10.1192/bjp.181.4.315

Cited by 117 publications

(79 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a relapse prevention study, patients who responded to 12 weeks of acute treatment with fluoxetine were re-randomized and continued in a 24-week phase with fluoxetine or placebo (Martenyi et al 2002a). In a relapseprevention study, subjects received open-label treatment for 6 months followed by doubleblind randomized treatment with fluoxetine or placebo for 6 months: fluoxetine was superior to placebo .…”

Section: Post-traumatic Stress Disorder (Ptsd)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Post-traumatic Stress Disorder (Ptsd)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

show abstract

“…Martenyi et al (2002b) rerandomized responders of an earlier 12-week placebo controlled trial of fluoxetine to either double-blind continuation treatment or placebo for a further 24 weeks. Continuation treatment with active medication was associated with a significantly longer time to relapse as well as additional improvement in not only PTSD but also in symptoms of comorbid disorders.…”

Section: Selective Serotonin Reuptake Inhibitors (Ssris)mentioning

confidence: 99%

Pharmacotherapy of Post-Traumatic Stress Disorder

Ravindran

Stein

2009

Current Topics in Behavioral Neurosciences

View full text Add to dashboard Cite

“…Alcuni lavori clinici controllati, condotti negli ultimi anni, hanno dimostrato una buona efficacia della fluoxetina, significativamente superiore al placebo, nel trattamento del disturbo da stress post-traumatico in gruppi di civili e di militari [82][83][84][85][86][87].…”

Section: B Disturbo Da Stress Post-traumaticounclassified

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Pepa

Eandi

2003

View full text Add to dashboard Cite

Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this paper we review the scientific and clinical research on fluoxetine that has been published in the last six years, as the prior work has been extensively examined in a review conducted on the tenth anniversary of its introduction on the market. The review focuses on cost minimization strategies that can be conducted following the introduction of low cost generic fluoxetine.

show abstract

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

Abstract: Fluoxetine is effective and well tolerated in the prevention of PTSD relapse for up to 6 months.

Cited by 117 publications

References 29 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Pharmacotherapy of Post-Traumatic Stress Disorder

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Contact Info

Product

Resources

About